Every Form 4 that Replimune Group, Inc. (REPL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow REPL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full REPL filings page.
Replimune Group, Inc. (REPL) director Philip Astley-Sparke reported a bona fide gift of 50,000 shares of common stock on 2026-08-20, transferred to a donor-advised fund. The transaction carried a reported price of $0.00 per share and was classified as a disposition. Following the gift, Astley-Sparke directly holds 1,362,414 shares of Replimune common stock.
Replimune Group, Inc. (REPL) reported that its Chief Financial Officer, Emily Luisa Hill, sold 9,256 shares of common stock on 2026-08-17 at a weighted average price of $14.28 per share. The shares were sold to cover tax withholding obligations arising from the partial vesting of her Restricted Stock Units under an irrevocable "sell to cover" provision and are described as not a discretionary sale. Following this transaction, Hill directly holds 215,852 shares of Replimune common stock.
Replimune Group, Inc. director and Chief Executive Officer Sushil Patel reported a sale of 39,341 shares of common stock on 2026-08-10 at $12.97 per share. According to the disclosure, these shares were sold to cover tax withholding obligations arising from the vesting of performance-based restricted stock units under an irrevocable "sell to cover" provision and do not represent a discretionary sale. Following this transaction, Patel directly holds 708,151 shares of Replimune common stock.
Replimune Group, Inc. Chief Financial Officer Emily Luisa Hill reported a sale of 11,448 shares of common stock on 2026-08-10 at $12.97 per share. According to the disclosure, the shares were sold to cover tax withholding obligations upon vesting of performance-based RSUs and were executed under an irrevocable “sell to cover” provision, leaving her with 225,108 shares held directly.
Replimune Group, Inc. Chief Medical Officer Konstantinos Xynos reported a sale of 11,447 shares of common stock on 2026-08-10 at $12.97 per share. According to the disclosure, the shares were sold to cover tax withholding obligations upon vesting of performance-based RSUs under an irrevocable "sell to cover" provision and were not a discretionary sale. Following this transaction, Xynos directly holds 224,215 shares of Replimune common stock.
Replimune Group, Inc. Chief Accounting Officer Andrew Schwendenman reported a sale of 7,632 shares of common stock on 2026-08-10 at $12.97 per share. According to the company disclosure, the shares were sold solely to cover tax withholding obligations arising from the vesting of performance-based restricted stock units under an irrevocable “sell to cover” provision, and were not a discretionary sale. Following the transaction, Schwendenman directly holds 99,425 shares of Replimune common stock.
Replimune Group, Inc. reported that investment funds advised by Baker Bros. Advisors LP purchased a total of 2,736,340 "2026 $0.0001 Prefunded Warrants" in an underwritten public offering that closed on August 11, 2026, at $12.0599 per warrant. Each warrant is exercisable immediately on a 1-for-1 basis into Common Stock at an exercise price of $0.0001 per share, subject to a 4.99% beneficial ownership cap, which the funds may adjust up to 19.99% effective 61 days after written notice. The Baker entities and individuals disclaim beneficial ownership beyond their pecuniary interest.
Replimune Group Chief Commercial Officer Christopher Sarchi sold 12,000 shares of common stock in an open-market transaction. The sale occurred on June 1, 2026 at a weighted average price of $9.24 per share, with individual trade prices ranging from $9.15 to $9.62 per share.
After this transaction, Sarchi directly holds 180,962 Replimune shares. The filing notes that the sale was executed under a pre-arranged trading plan adopted on December 15, 2025 intended to comply with Rule 10b5-1(c), indicating it was scheduled in advance rather than timed discretionarily.
Replimune Group, Inc. Chief Medical Officer Konstantinos Xynos reported an open-market sale of 14,023 shares of common stock on May 18, 2026 at a weighted average price of $5.08 per share. According to the disclosure, the shares were sold solely to cover tax withholding obligations from the partial vesting of his Restricted Stock Units under an irrevocable “sell to cover” provision, meaning the transaction was not a discretionary sale. After this tax-related sale, he continues to hold 235,662 shares directly.
Replimune Group, Inc. Chief Accounting Officer Andrew Schwendenman reported an open-market sale of 7,894 shares of common stock at a weighted average price of $5.08 per share. According to the disclosure, the shares were sold solely to cover tax withholding obligations arising from a partial vesting of his Restricted Stock Units under a pre-set “sell to cover” provision, rather than a discretionary sale. Following this transaction, he directly holds 107,057 shares of Replimune common stock.
Replimune Group, Inc.’s Chief Commercial Officer Christopher Sarchi reported an open-market sale of 8,626 shares of common stock at a weighted average price of $5.08 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations tied to a partial vesting of his restricted stock units under an irrevocable “sell to cover” provision, meaning the transaction was not a discretionary sale. After this tax-related sale, Sarchi directly holds 192,962 shares of Replimune common stock.
Replimune Group, Inc. director Philip Astley-Sparke reported an open-market sale of 17,657 shares of common stock at a weighted average price of $5.08 per share. The shares were sold under an irrevocable “sell to cover” provision to satisfy tax withholding on partially vesting RSUs and are described as non-discretionary.
The filing notes the trades occurred at prices ranging from $5.02 to $5.08 per share. Following this tax-related sale, Astley-Sparke directly holds 1,412,414 shares of Replimune common stock.
Replimune Group, Inc. director and Chief Executive Officer Sushil Patel reported selling 37,324 shares of common stock at a weighted average price of $5.08 per share. According to the disclosure, the shares were sold solely to cover tax withholding obligations from the partial vesting of his Restricted Stock Units.
The sales occurred in multiple transactions at prices ranging from $5.01 to $5.08 per share under an irrevocable “sell to cover” provision in the RSU award agreements, described as non-discretionary. Following these transactions, Patel directly holds 747,492 shares of Replimune common stock.
Replimune Group, Inc. Chief Financial Officer Emily Luisa Hill reported an open-market sale of 7,812 shares of common stock. The shares were sold at a weighted average price of $5.08 per share to cover tax withholding obligations tied to the partial vesting of her Restricted Stock Units.
The sale was executed under an irrevocable “sell to cover” provision in the RSU award agreements and is described as not representing a discretionary sale by the reporting person. After these transactions, she directly holds 236,556 shares of Replimune common stock.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
Replimune Group, Inc. disclosed a compensation-related grant of 44,500 non-qualified stock options to director Michael Goller, a full-time employee of Baker Bros. Advisors LP. The options are exercisable into Common Stock at a $7.61 strike price, vest on April 1, 2027 subject to continued board service or a change in control, and expire on April 1, 2036. Baker Bros. Advisors has voting and dispositive power over these options, while affiliated Baker Bros. funds and principals hold only an indirect pecuniary interest and expressly disclaim beneficial ownership beyond that interest. The same 44,500-option grant is reported for each fund that shares this indirect interest.
Replimune Group, Inc. disclosed that Chief Commercial Officer Christopher Sarchi received new equity awards as part of his compensation. He was granted employee stock options for 75,000 shares of common stock at an exercise price of $7.61 per share, vesting 25% on April 1, 2027 and monthly thereafter until fully vested. He also received 50,000 restricted stock units (RSUs), each representing one share of common stock, vesting 25% on May 15, 2027 and then in three approximately equal annual installments through May 15, 2030, subject to continued service. Following these awards, he directly holds 201,588 shares of common stock. These are compensation grants, not open‑market purchases or sales.
Replimune Group director Philip Astley-Sparke reported compensation-related equity awards. He received a stock option for 75,000 shares of common stock at an exercise price of 7.6100 per share, expiring on April 1, 2036. Twenty-five percent of this option vests on April 1, 2027, with the rest vesting in 36 approximately equal monthly installments.
He also received 50,000 shares of common stock issuable upon settlement of restricted stock units, with 25% vesting on May 15, 2027 and the remainder in three approximately equal annual installments through May 15, 2030, subject to continuous service. Following the grant, he directly holds 1,430,071 common shares. These are grants/awards, not open-market purchases or sales.
Replimune Group, Inc. director Christy J. Oliger received a grant of stock options covering 44,500 shares of common stock. The options have an exercise price of $7.61 per share and expire on April 1, 2036.
According to the filing footnote, all shares underlying this option vest on April 1, 2027. Following this grant, Oliger holds stock options for 44,500 shares directly, reflecting a compensation-related award rather than an open-market trade.
Replimune Group, Inc. reported that Chief Medical Officer Konstantinos Xynos received new equity awards as part of his compensation. He was granted an employee stock option for 75,000 shares of common stock at an exercise price of $7.61 per share, expiring on April 1, 2036. Twenty‑five percent of these option shares will vest on April 1, 2027, with the remainder vesting in 36 roughly equal monthly installments.
He also acquired 50,000 shares of common stock through restricted stock units (RSUs). Each RSU represents one share of common stock, with 25% vesting on May 15, 2027 and the rest vesting in three approximately equal annual installments until May 15, 2030, subject to continued service. Following these grants, he directly owns 249,685 common shares.
Replimune Group, Inc. director Madhavan Balachandran received a grant of stock options covering 44,500 shares of common stock. The options have an exercise price of $7.61 per share and expire on April 1, 2036. According to the footnote, all underlying shares vest on April 1, 2027.
Replimune Group, Inc. reported that Chief Accounting Officer Andrew Schwendenman received new equity awards. He was granted an employee stock option for 55,000 shares of common stock at an exercise price of $7.61 per share, vesting 25% on April 1, 2027 and then in 36 monthly installments until expiration on April 1, 2036. He was also awarded 36,667 shares of common stock issuable upon settlement of restricted stock units, vesting 25% on May 15, 2027 and then in three annual installments through May 15, 2030, contingent on continued service. Following these grants, he directly holds 114,951 shares of common stock, plus the newly granted options.
Replimune Group, Inc. disclosed that Chief Executive Officer Sushil Patel received new equity awards as part of his compensation. He was granted an employee stock option for 376,860 shares of common stock at an exercise price of $7.61 per share, expiring on April 1, 2036. According to the vesting schedule, 25% of the option vests on April 1, 2027, with the remainder vesting in 36 approximately equal monthly installments. Patel also received 251,240 restricted stock units (RSUs), each representing one share of common stock. The RSUs vest 25% on May 15, 2027, with the balance vesting in three approximately equal annual installments through May 15, 2030, contingent on continued service. Following these awards, he directly owns 784,816 shares of common stock. These are compensation-related grants rather than open-market purchases.
Replimune Group director Kapil Dhingra received a grant of stock options covering 44,500 shares of Common Stock. The options have an exercise price of $7.61 per share and expire on April 1, 2036. All underlying shares vest together on April 1, 2027, and no open-market buy or sell occurred.
Replimune Group, Inc. director Paolo Pucci received a grant of stock options covering 44,500 shares of Common Stock. The options have a per-share exercise price of $7.61 and expire on April 1, 2036. All underlying shares vest in a single tranche on April 1, 2027. This is a compensation-related award rather than an open-market purchase or sale, and after this grant Pucci holds 44,500 stock options directly.
Replimune Group, Inc. director Joseph P. Slattery received a grant of stock options covering 44,500 shares of common stock. The options have an exercise price of $7.61 per share and expire on April 1, 2036. According to the disclosure, all 44,500 underlying shares vest in full on April 1, 2027. Following this grant, Slattery holds 44,500 stock options directly.
Replimune Group, Inc. director Veleka Peeples-Dyer received a grant of stock options covering 44,500 shares of common stock. The options have an exercise price of $7.61 per share and expire on April 1, 2036. All underlying shares vest on April 1, 2027, making this a compensation-related, non-market transaction.
Replimune Group, Inc. Chief Financial Officer Emily Luisa Hill reported receiving new equity awards. She was granted an employee stock option for 75,000 shares of common stock at an exercise price of $7.61 per share, expiring on April 1, 2036. Twenty-five percent of this option vests on April 1, 2027, with the rest vesting in 36 approximately equal monthly installments.
Hill was also granted 50,000 restricted stock units (RSUs), each representing one share of common stock. Twenty-five percent of these RSUs vest on May 15, 2027, with the remainder vesting in three approximately equal annual installments until May 15, 2030, subject to continued service. Following the RSU grant, her direct common stock holdings increased to 244,368 shares.
Replimune Group, Inc. director Weinand Dieter received a grant of stock options covering 44,500 shares of common stock. The options have an exercise price of $7.61 per share and expire on April 1, 2036.
According to the filing, these options vest in full on April 1, 2027. Following this grant, Dieter holds 44,500 derivative securities directly, reflecting a compensation award rather than an open-market purchase.
Replimune Group, Inc. Chief Commercial Officer Christopher Sarchi sold 6,500 shares of common stock in an open-market transaction. The shares were sold on April 2, 2026 at a weighted average price of $8.01 per share, in multiple trades between $8.00 and $8.06.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2025, indicating it was scheduled in advance. After this sale, Sarchi beneficially owns 151,588 shares of Replimune common stock, including restricted stock units, and holds options to acquire an additional 250,425 shares, 142,555 of which are currently exercisable.
Replimune Group, Inc. director Philip Astley-Sparke reported a disposition of shares through a bona fide gift. He transferred 25,000 shares of Common Stock at a reported price of $0.00 per share, characterized as a gift transfer.
After this transaction, his directly held ownership was reported as 1,380,071 shares of Common Stock. The filing reflects a charitable or personal transfer rather than an open-market sale, so it does not indicate cash proceeds to the director.
Replimune Group, Inc. director reported an option exercise and share sale on 12/09/2025. The director exercised a stock option for 3,169 shares of common stock at an exercise price of $1.75 per share (transaction code M), then sold 3,169 shares of common stock at $10.4 per share the same day (transaction code S). After these transactions, the director reported beneficial ownership of 0 shares of common stock and 0 derivative securities from this option grant.
The disclosure explains that the option was exercised due to the upcoming 01/21/2026 expiration date, and that all 3,169 shares underlying this stock option had vested on 01/21/2016.
Replimune Group, Inc. (REPL) reported an insider transaction by its Chief Commercial Officer, who filed a Form 4 as a single reporting person. On 11/17/2025, the officer sold 5,208 shares of Replimune common stock in a transaction coded "S" for sale. The sale was executed at a broker-calculated weighted average price of $9.10 per share, with individual trades ranging from $8.88 to $9.26 per share.
The shares were sold solely to cover tax withholding obligations arising from the partial vesting of the officer’s restricted stock units under an irrevocable "sell to cover" provision, and are described as non-discretionary. Following this transaction, the officer beneficially owns 123,088 shares of Replimune common stock in direct ownership.
Replimune Group, Inc. (REPL) reported an insider transaction by its Chief Medical Officer. On 11/17/2025, the officer sold 7,248 shares of common stock in a transaction coded "S" at a weighted average price of $9.10 per share. The company explains this was an automatic sale to cover tax withholding obligations tied to the partial vesting of previously granted Restricted Stock Units under an irrevocable "sell to cover" provision, rather than a discretionary sale.
After this transaction, the officer beneficially owns 139,685 shares of Replimune common stock in direct ownership. The shares were sold as part of a block trade in multiple transactions at prices ranging from $8.88 to $9.26 per share, with detailed pricing information available on request.